Last updated: February 20, 2026
What is NDC 72205-0106?
NDC 72205-0106 corresponds to Naxaltrex (brand name pending approval), a medication in the opioid antagonists class. The drug is primarily designed for opioid overdose reversal but also has potential off-label applications in alcohol use disorder.
Market Landscape
Indications and Patient Population
- Primary Use: Opioid overdose treatment.
- Eligible Population: Emergency departments, addiction clinics, and hospitals.
- Estimated Market Size:
- US opioid overdose emergency visits: approximately 650,000 annually.[1]
- Hospitalizations for opioid overdose: roughly 300,000 annually.[2]
Competitors and Market Share
| Drug Name |
Therapeutic Class |
Market Share (2022) |
Price Range (per dose) |
Approval Status |
| Naloxone (Narcan) |
Opioid antagonist |
85% |
$35 - $50 |
FDA approved (2015) |
| Nalmefene |
Opioid antagonist |
Minority |
$150+ |
Approved in Europe, not US |
| Naxaltrex (pending) |
Opioid antagonist (candidate) |
Not on market yet |
Unknown |
Under FDA review |
Regulatory Timeline
- FDA Filing: Submitted January 2022.
- Estimated FDA Approval: Q3 2023 based on typical review cycles.
- Potential Launch: Q4 2023 to Q1 2024, assuming approval.
Reimbursement Environment
- Medicaid and Medicare reimbursements typically align with established opioid antagonists.
- Reimbursement codes likely to be similar to existing drugs such as Narcan, with variations based on administration method.
Pricing Dynamics and Projections
Current Market Prices
- Naloxone: Cost per dose ranges from $35 to $50 in retail settings.
- Alternatives: Injectable formulations can reach $150+ per dose.
Suggested Pricing for Naxaltrex
- Initial estimation: $75 - $100 per dose.
- Rationale:
- Positioned as a potentially more effective or longer-lasting product.
- Direct competition with Narcan, which has seen prices spike due to demand.
Price Trajectories
| Scenario |
Timeline |
Price Range per Dose |
Key Factors |
| Conservative |
2024-2025 |
$75 - $90 |
Entry at competitive price with Narcan |
| Moderate Growth |
2024 - 2026 |
$85 - $100 |
Differentiation through formulation, efficacy |
| Aggressive Expansion |
2025 onwards |
$90 - $120 |
Premium positioning if superior safety/efficacy |
Market Penetration Considerations
- Early marketing efforts focus on hospitals and ERs.
- Payer negotiations influence final pricing.
- Post-approval clinical data may allow premium pricing.
Key Competitive Advantages
- Faster onset of action.
- Longer duration to prevent repeat overdoses.
- Reduced side effects profile.
- Easier administration process.
Risks and Challenges
- Limited initial market share until proven superior.
- Pricing pressure from existing alternatives.
- Payer and insurer negotiation hurdles.
- Potential delays in FDA approval or launch.
Summary
NDC 72205-0106, Naxaltrex, is poised for entry into a crowded opioid reversal market dominated by Narcan. Its success depends on clinical differentiation, pricing strategy, and reimbursement negotiations. Initial pricing likely in the $75–$100 range, with potential for adjustments based on clinical data and market uptake.
Key Takeaways
- Naxaltrex faces competition from established naloxone products with retail prices around $35–$50 per dose.
- Pricing projections range from $75 to $100 initially, with scope for higher prices if clinical benefits are significant.
- Market entry hinges on FDA approval and payer acceptance.
- The opioid overdose reversal market had a projected US value exceeding $1 billion annually in 2022.
- Differentiation through formulation and safety profile offers potential for premium pricing.
FAQs
1. When is FDA approval expected for Naxaltrex?
Estimated during Q3 2023, with launch possibilities in late 2023 to early 2024.
2. How does Naxaltrex differ from Narcan?
Key differences are expected to include faster onset and longer duration, although clinical data is pending.
3. What are primary reimbursement challenges?
Negotiating coverage with payers and establishing a new billing code. Existing reimbursement codes for naloxone products are well-established.
4. How will pricing impact market adoption?
Higher prices may limit rapid adoption initially, but clinical advantages could justify premium pricing.
5. What is the potential market size post-launch?
Approximately 600,000 to 700,000 annual US overdose cases with potential full market penetration within 3-5 years.
References
- CDC (2022). Emergency department visits for drug poisoning, United States. https://www.cdc.gov/nchs/nvss/drug-overdose.htm
- CDC (2022). Hospitalizations for opioid overdose. https://www.cdc.gov/nchs/nvss/drug-overdose.htm
